Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis.

#1238

Introduction: Renal impairment may alter the normal pharmacokinetic and pharmacodynamic behavior of chemotherapy drugs, thus increasing the risk of side effects. Everolimus was reported to have anti-tumor activity in bronchial neuroendocrine tumors (NET). Safety and toxicity profile of everolimus has been provided in hemodialyzed patients with renal cell carcinoma. Only a report describes the effect of everolimus in a patient with metastatic ileac carcinoid in hemodialysis.

Aim(s): To test the feasibility of everolimus in a patient with metastatic atypical bronchial carcinoid receiving hemodialysis.

Materials and methods: A 47 year-old man suffering from a metastatic atypical bronchial carcinoid, in hemodialysis, had radiologic and clinical progressive disease after treatment with somatostatin analogues. Patient received oral everolimus.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Brizzi M, Sonetto C, Bitossi R, Baratelli C, Volante M,

Keywords: Bronchial carcinoid, everolimus, hemodialysis,